Skip to main content
SpringerLink
Log in

Assessment of the Pharmacokinetic Interaction between Zileuton and Digoxin in Humans

  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

The effects of coadministration of zileuton on the pharmacokinetic profile of digoxin were investigated in a double-blind placebo-controlled crossover study in 12 healthy male volunteers. During each study phase, the subjects received zileuton 600mg every 6 hours (regimen A) or placebo (regimen B) for 13 days. In addition, all subjects received concomitant digoxin 0.25 mg/day on study days 1 to 11 during both study phases.

The study results provide no evidence of any significant overall effect of zileuton on digoxin plasma concentration-time profiles. Although the mean time to reach the maximum plasma concentration for digoxin was significantly shorter after concomitant administration of digoxin and zileuton than after concomitant administration of digoxin and placebo (0.95 vs 1.43 hours), there were no significant differences between the 2 regimens in the values for maximum plasma concentration, area under the plasma concentration-time curve from 0 to 24 hours, elimination half-life, oral clearance, and apparent volume of distribution associated with the terminal phase.

Therefore, it is concluded that digoxin and zileuton may be coadministered without risk of clinically relevant effects on the pharmacokinetic profile of digoxin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Samuelsson B, Dahlen S-E, Lindgren JA, et al. Leukotrienes and lipoxines: structures, biosynthesis and biological effects. Science 1987; 237: 1171–6

    Article  PubMed  CAS  Google Scholar 

  2. Brain SD, Williams TJ. Leukotrienes and inflammation. Pharmacol Ther 1990; 46: 57–66

    Article  PubMed  CAS  Google Scholar 

  3. Carter GW, Young PR, Albert DH, et al. A-64077, a new potent orally active 5-lipoxygenase inhibitor. In: Zor U, Naor Z, Danon A, editors. Leukotrienes and prostanoids in health and disease, new trends in lipid mediator research. Vol. 3: Basel: Karger, 1989; 50–5

    Google Scholar 

  4. Carter GW, Young PR, Albert DH, et al. 5-Lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 1991; 256: 929–37

    PubMed  CAS  Google Scholar 

  5. Israel E, Dermarkarian R, Rosenberg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990; 323: 1740–4

    Article  PubMed  CAS  Google Scholar 

  6. Israel E, Drazen J, Pearlman H, et al. Adouble-blind multicenter study of zileuton, a potent 5-lipoxygenase inhibitor (5-LO) versus placebo in the treatment of spontaneous asthma in adults. J Allergy Clin Immunol 1992; 89 (1 Pt 2): 236

    Google Scholar 

  7. Hui KP, Taylor IK, Taylor GW, et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991; 46: 184–9

    Article  PubMed  CAS  Google Scholar 

  8. Reunig RH, Geraets DR. Digoxin. In: Evans WE, Schentag JJ, Jusko WJ, et al., editors. Applied pharmacokinetics, principles of therapeutic drug monitoring. 2nd ed. Washington: Applied Therapeutics, Inc., 1986: 570

    Google Scholar 

  9. Hoffman BF, Bigger Jr JT. Digitalis and allied cardiac glycosides. In: Gilman AG, Goodman LS, Rall TW, editors. The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985: 743

    Google Scholar 

  10. Gibaldi M, Perrier P. Noncompartmental analysis based on statistical moment theory. In: Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982: 409–16

    Google Scholar 

  11. Bigger Jr JT, Strauss HC. Digitalis toxicity: drug interactions promoting toxicity and the management of toxicity. Semin Drug Treat 1972; 2: 147–77

    PubMed  CAS  Google Scholar 

  12. McNeil JJ, Sloman JG. Cardiovascular diseases. In: Speight TM, editor. Avery’s drug treatment. Principles and practice of clinical pharmacology and therapeutics. 3rd ed. New Zealand: Adis Press, 1987: 650–1

    Google Scholar 

  13. Klein HO, Lang R, Segni EDI, et al. Verapamil digoxin interaction. New Engl J Med 1980; 303: 160

    PubMed  CAS  Google Scholar 

  14. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes, editor. Side effects of drugs. 10th ed. New York: Elsevier, 1986: 142

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacokinetics and Biopharmaceutics Department, Abbott Laboratories, D4PK, API3A, 100 Abbott Park Road, Abbott Park, Illinois, 60064-3500, USA

    Walid M. Awni, Ziad Hussein & G. Richard Granneman

  2. Clinical Pharmacology Department, Abbott Laboratories, Abbott Park, Illinois, USA

    John H. Cavanaugh

  3. The Immunoscience Venture, Abbott Laboratories, Abbott Park, Illinois, USA

    Louise M. Dubé

Authors
  1. Walid M. Awni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ziad Hussein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John H. Cavanaugh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Richard Granneman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Louise M. Dubé
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Awni, W.M., Hussein, Z., Cavanaugh, J.H. et al. Assessment of the Pharmacokinetic Interaction between Zileuton and Digoxin in Humans. Clin-Pharmacokinet 29 (Suppl 2), 92–97 (1995). https://doi.org/10.2165/00003088-199500292-00013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199500292-00013

Keywords

Search

Navigation